Standard BioTools (LAB) Jefferies London Healthcare Conference 2024 summary

Strategic vision and business model

• Focused on building a sustainable, high-margin business in life science tools, emphasizing operational efficiency and profitability.

• Operates with an owner-investor mindset, prioritizing return on investment, diversification, and downside mitigation.

• Developed the Standard BioTools Business System (SBS) to drive lean operations and continuous improvement.

• Executed transformative acquisitions and leverages significant R&D investments to build a robust product portfolio.

• Maintains a seasoned leadership team with experience from leading industry organizations such as Danaher, Roche, Pfizer, and GSK.

Financial performance and cost management

• Achieved or reiterated FY24 revenue guidance of $170–$175 million, with a 53% gross margin and over 80% of revenue from consumables and services.

• Realized $80 million in cost synergies a year ahead of schedule, with a 50% year-over-year improvement in adjusted EBITDA.

• Q3 reported $368 million in cash and investments, supporting ongoing M&A and profitability goals.

• Targets break-even adjusted EBITDA by 2026, with ongoing efforts to optimize OpEx and drive commercial growth.

• Uses non-GAAP financial measures to benchmark performance and guide strategic decisions.

Product and market strategy

• Business mix is over 50% services, with a strategic shift toward higher-margin consumables and future target of 65% gross margins.

• Omics as a Service and the SomaScan platform are key growth drivers, with expansion into distributed solutions and new partnerships.

• Partnership with Illumina expected to launch in the first half of 2025, structured with upfront payment and ongoing royalties.

• Offering individual reagents from the SomaScan assay as a new growth vector.

• Exploring opportunities in bioproduction, clinical, and pharma/biotech markets through organic and inorganic growth.